Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Evaluation of patient-level retrieval from electronic health record data for a cohort discovery task
Chamberlin, Steven , Cohen, Aaron , Wang, Yanshan , Hersh, William , Liu, Sijia , Hersh, William , Wang, Yanshan , Bedrick, Steven , Wen, Andrew , Liu, Hongfang

Mayo Clinic

JAMIA Open | July 26, 2020 | Volume: 3 | Issue: 3 | Pages: 395-404

10.1093/jamiaopen/ooaa026 | PMID 33215074 Get It

Abstract Objective Growing numbers of academic medical centers offer patient cohort discovery tools to their researchers, yet the performance of systems for this use case is not well understood. The objective of this research was to assess patient-level information retrieval methods using electronic health records for different types of cohort definition retrieval. Materials and Methods We developed a test collection consisting of about 100 000 patient records and 56 test topics that characterized patient cohort requests for various clinical studies. Automated information retrieval tasks using word-based approaches were performed, varying 4 different parameters for a total of 48 permutations, with performance measured using B-Pref. We subsequently created structured Boolean queries for the 56 topics for performance comparisons. In addition, we performed a more detailed analysis of 10 topics. Results The best-performing word-based automated query parameter settings achieved a mean B-Pref of 0.167 across all 56 topics. The way a topic was structured (topic representation) had the largest impact on performance. Performance not only varied widely across topics, but there was also a large variance in sensitivity to parameter settings across the topics. Structured queries generally performed better than automated queries on measures of recall and precision but were still not able to recall all relevant patients found by the automated queries. Conclusion While word-based automated methods of cohort retrieval offer an attractive solution to the labor-intensive nature of this task currently used at many medical centers, we generally found suboptimal performance in those approaches, with better performance obtained from structured Boolean queries. Future work will focus on using the test collection to develop and evaluate new approaches to query structure, weighting algorithms, and application of semantic methods.
Establishing a density-based method to separate proliferating and senescent cells from bone marrow stromal cells
Xu, Fei , Zhang, Qiang , Wang, Haitao

Mayo Clinic

Aging | July 25, 2020 | Volume: 12 | Issue: 14 | Pages: 15050-15057

10.18632/aging.103569 | PMID 32710730 Get It

Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
Seligson, Nathan D. , Warner, Jeremy L. , Dalton, William S. , Martin, David , Miller, Robert S. , Patt, Debra A. , Kehl, Kenneth L. , Palchuk, Matvey B. , Alterovitz, Gil , Wiley, Laura K. , Shen, Feichen , Wang, Yanshan , Nguyen, Khoa A. , Wong, Anthony, Chen, James L. , Warner, Jeremy L , Miller, Robert S , Wiley, Laura K , Wang, Yanshan , Huang, Ming , Meric‐Bernstam, Funda , Bernstam, Elmer V

Mayo Clinic

Journal of the American Medical Informatics Association | July 24, 2020 | Volume: 27 | Issue: 11 | Pages: 1808-1812

10.1093/jamia/ocaa159 | PMID 32885823 Get It

Abstract Defining patient-to-patient similarity is essential for the development of precision medicine in clinical care and research. Conceptually, the identification of similar patient cohorts appears straightforward; however, universally accepted definitions remain elusive. Simultaneously, an explosion of vendors and published algorithms have emerged and all provide varied levels of functionality in identifying patient similarity categories. To provide clarity and a common framework for patient similarity, a workshop at the American Medical Informatics Association 2019 Annual Meeting was convened. This workshop included invited discussants from academics, the biotechnology industry, the FDA, and private practice oncology groups. Drawing from a broad range of backgrounds, workshop participants were able to coalesce around 4 major patient similarity classes: (1) feature, (2) outcome, (3) exposure, and (4) mixed-class. This perspective expands into these 4 subtypes more critically and offers the medical informatics community a means of communicating their work on this important topic.
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
Cairns, Junmei , Ingle, James N. , Dudenkov, Tanda M., Na, Jie , Buzdar, Aman U. , Robson, Mark E. , Ellis, Matthew J. , Goss, Paul E. , Shepherd, Lois E. , Goodnature, Barbara, Weinshilboum, Richard M. , Bari, Mehrab Ghanat, Wang, Liewei , Ingle, J , Ellis, Matthew J , Na, Jie , Robson, Mark , Kalari, Krishna R. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M. , Li, Hu

Mayo Clinic

JCI Insight | July 23, 2020 | Volume: 5 | Issue: 16 | Pages: No page available

10.1172/jci.insight.137571 | PMID 32701512 Get It

Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exemestane, we identified a single nucleotide polymorphism (SNP) in CUB And Sushi multiple domains 1 ( CSMD1) associated with breast cancer–free interval, with the variant allele associated with fewer distant recurrences. Mechanistically, CSMD1 regulates CYP19 expression in an SNP- and drug-dependent fashion, and this regulation is different among 3 AIs: anastrozole, exemestane, and letrozole. Overexpression of CSMD1 sensitized AI-resistant cells to anastrozole but not to the other 2 AIs. The SNP in CSMD1 that was associated with increased CSMD1 and CYP19 expression levels increased anastrozole sensitivity, but not letrozole or exemestane sensitivity. Anastrozole degrades estrogen receptor α (ERα), especially in the presence of estradiol (E2). ER + breast cancer organoids and AI- or fulvestrant-resistant breast cancer cells were more sensitive to anastrozole plus E2 than to AI alone. Our findings suggest that the CSMD1 SNP might help to predict AI response, and anastrozole plus E2 serves as a potential new therapeutic strategy for patients with AI- or fulvestrant-resistant breast cancers.
Association between chocolate consumption and risk of coronary artery disease: a systematic review and meta-analysis
Krittanawong, Chayakrit , Narasimhan, Bharat , Hahn, Joshua , Zhang, HongJu, Tang, W.H. Wilson , Farrell, Ann M, Tang, W H Wilson , Wang, Zhen , Virk, Hafeez Ul Hassan , Farrell, Ann

Mayo Clinic

European Journal of Preventive Cardiology | July 22, 2020 | Volume: 28 | Issue: 12 | Pages: e33-e35

10.1177/2047487320936787 | PMID 34647587 Get It

Generating Real-World Evidence from Unstructured Clinical Notes to Examine Clinical Utility of Genetic Tests: Use Case in BRCAness
Zhao, Yiqing , Weroha, Saravut J., Goode, Ellen, Wang, Chen , Wang, Chen , Liu, Hongfang

Mayo Clinic

No container title available | July 21, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-41553/v1 Get It

Abstract Background: Next-generation sequencing provides comprehensive information about individuals’ genetic makeup and is commonplace in oncology clinical practice. However, the utility of genetic information in clinical decision-making process has not been examined extensively from a real-world, data-driven perspective. Through mining real-world data (RWD) from clinical notes, we could extract patients’ genetic information and further associate treatment decisions with genetic information.Methods: We proposed a real-world evidence (RWE) study framework that incorporates context-based natural language processing (NLP) methods and data quality examination before final association analysis. The framework was demonstrated on a Foundation-tested women cancer cohort (N=196). Upon retrieval of patients’ genetic information using NLP system, we assessed completeness of genetic data captured in unstructured clinical notes according a genetic data-model. We examined the distribution of different topics regarding BRCA1/2 throughout patients’ treatment process, and then analyzed the association between BRCA1/2 mutation status and the discussion/prescription of targeted therapy. Results: We identified seven topics in clinical context of genetic mentions including: Information, Evaluation, Insurance, Order, Negative, Positive, and Variants of unknown significance (VUS). Our rule-based system achieved a precision of 0.87, recall of 0.93 and F-measure of 0.91. Our machine learning system achieved a precision of 0.901, recall of 0.899 and F-measure of 0.9 for four-topic classification and a precision of 0.833, recall of 0.823 and F-measure of 0.82 for seven-topic classification. We found in result-containing sentences, capture of BRCA1/2 mutation information was 75%, but detailed variant information (e.g. variant types) is largely missing. Using cleaned RWD, significant associations were found between BRCA1/2 positive mutation and targeted therapies.Conclusions: In conclusion, we demonstrated a framework to generate RWE using RWD from different clinical sources. Rule-based NLP system achieved the best performance for resolving contextual variability when extracting RWD from unstructured clinical notes. Data quality issue such as incompleteness and discrepancies exist thus manual data cleaning is needed before further analysis can be performed. Finally, we were able to use cleaned RWD to evaluate real-world utility of genetic information to initiate prescription of targeted therapy.
Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis, and treatmen
Ng, Bobby G. , Eklund, Erik A. , Shiryaev, Sergey A., Dong, Yin Yao , Abbott, Mary‐Alice , Asteggiano, Carla , Bamshad, Michael J. , Barr, Eileen , Bernstein, Jonathan A. , Chelakkadan, Shabeed, Ciliberto, Michael A. , Cousin, Janice, Gardiner, Fiona, Ghosh, Suman , Graf, W. , Grünewald, Stephanie , Hammond, Katherine, Hauser, Natalie , Hoganson, George, Houck, Kimberly , Kohler, Jennefer N., Liu, Pengfei , Madathil, Sujana , McCormack, Colleen E., Meeks, Naomi, Miller, Rebecca L. , Monaghan, Kristin G. , Nickerson, Deborah A. , Palculict, Timothy Blake, Papazoglu, Gabriela M., Pletcher, Beth A. , Scheffer, Ingrid E. , Schenone, Andrea, Schnur, Rhonda E. , Si, Yue , Rowe, Leah J., Russi, Alvaro H. Serrano, Russo, Rossana Sanchez , Thabet, Farouq , Tuite, Allysa , Villanueva, Marıá Mercedes, Webster, Richard , Wilson, Dorcas, Zalan, Alice, Wolfe, Lynne A. , Rhodes, Lindsay, Scheffer, Ingrid E , Ng, Bobby G , Christodoulou, John , Chung, Wendy K. , Morava, Éva , Larson, Austin , Miller, Rebecca, Monaghan, Kristin G. , Rowe, Leah J., Wang, Raymond , Rosenfeld, Jill A. , Freeze, Hudson H.

Mayo Clinic

Journal of Inherited Metabolic Disease | July 18, 2020 | Volume: 43 | Issue: 6 | Pages: 1333-1348

10.1002/jimd.12290 | PMID 32681751 Get It

Abstract Asparagine‐linked glycosylation 13 homolog ( ALG13 ) encodes a nonredundant, highly conserved, X‐linked uridine diphosphate (UDP)‐ N ‐acetylglucosaminyltransferase required for the synthesis of lipid linked oligosaccharide precursor and proper N‐linked glycosylation. De novo variants in ALG13 underlie a form of early infantile epileptic encephalopathy known as EIEE36, but given its essential role in glycosylation, it is also considered a congenital disorder of glycosylation (CDG), ALG13‐CDG. Twenty‐four previously reported ALG13‐CDG cases had de novo variants, but surprisingly, unlike most forms of CDG, ALG13‐CDG did not show the anticipated glycosylation defects, typically detected by altered transferrin glycosylation. Structural homology modeling of two recurrent de novo variants, p.A81T and p.N107S, suggests both are likely to impact the function of ALG13. Using a corresponding ALG13‐deficient yeast strain, we show that expressing yeast ALG13 with either of the highly conserved hotspot variants rescues the observed growth defect, but not its glycosylation abnormality. We present molecular and clinical data on 29 previously unreported individuals with de novo variants in ALG13 . This more than doubles the number of known cases. A key finding is that a vast majority of the individuals presents with West syndrome, a feature shared with other CDG types. Among these, the initial epileptic spasms best responded to adrenocorticotropic hormone or prednisolone, while clobazam and felbamate showed promise for continued epilepsy treatment. A ketogenic diet seems to play an important role in the treatment of these individuals.
Deep Venous Thrombosis in COVID-19 Patients: A Cohort Analysis
You, Yun , Cai, Fei , Li, Yiqing , Yang, Lu , Ye, Dawei , Ling, Ken, Misra, Sanjay , Wang, Weici , Misra, Sanjay , Guo, Yi Chen , Hu, Ke , Xie, Mingxing , Ling, Ken, Cai, Chuanqi

Mayo Clinic

No container title available | July 15, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-39414/v1 Get It

Abstract BackgroundDeep venous thrombosis (DVT) is a severe complication of the coronavirus disease 2019 (COVID-19). It may interfere with COVID-19 treatment and delay the recovery, but there is less data about the anticoagulant therapy and sex difference of VTE in patients with COVID-19. The purpose of this study is to study the prevalence, risk factors, anticoagulant therapy and sex difference of deep venous thrombosis (DVT) in patients with COVID-19.MethodsThe enrolled 121 patients were confirmed positive for COVID-19. All suspected patients with a high Caprini index (≥4) or PADUA index (≥4) received color Doppler Ultrasound (US) to screen DVT in both lower extremities. Clinical characteristics of DVT-COVID-19 patients were analyzed. Multivariate logistic regression was performed to identify risk factors related to DVT in COVID-19 patients. The distribution of DVT locations, anticoagulation therapy with sex difference, and the outcomes were also analyzed.ResultsDVT was found in 48% asymptomatic COVID-19 patients with increased PAUDA index or Caprini index by US scanning. Multivariate logistic regression determined that age, CRP and baseline D-dimer were risk factors among COVDI-19 patients. Although the most common DVT location was infrapopliteal (Class I and Class II), higher mortality in DVT-COVID-19 patients was confirmed. DVT-COVID-19 patients presented significant increases in the CRP, neutrophil count and D-dimer throughout the whole inpatient period compared to non-DVT-COVID-19 patients. Although anticoagulation therapy accelerated the recovery of lymphocytopenia condition in DVT patients, men DVT-COVID-19 patients showed higher CRP and neutrophil count vs. lymphocyte count (N/L) ratio but lower lymphocyte count compared to women DVT-COVID-19 patients. ConclusionsDVT is common in COVID-19 patients with high risk factors, especially for older age, higher CRP and baseline D-dimer populations. It is important to consider sex differences in the anticoagulant therapy among DVT-COVID-19 patients.
Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26− or CD7− CD4+ T‐cells
Bah, Ismaël , Huen, Auris , Wang, Wei , Vega, Francisco , Craig, Fiona E. , Wang, Sa A. , Lyapichev, Kirill A , Craig, Fiona E , Vega, Francisco , Duvic, Madeleine , Routbort, Mark J. , Jorgensen, Jeffrey L. , Medeiros, L. Jeffrey

Mayo Clinic

Cytometry Part B: Clinical Cytometry | July 15, 2020 | Volume: 100 | Issue: 2 | Pages: 183-191

10.1002/cyto.b.21933 | PMID 32667737 Get It

AbstractBackgroundBlood involvement by mycosis fungoides (MF)/Sézary syndrome (SS) influences prognosis and therapeutic decisions. MF/SS blood stage is currently determined by absolute CD4 + CD26− or CD4 + CD7‐cell counts, which quantification method may overestimate MF/SS by including CD26− or CD7− normal CD4+ T‐cells, or underestimate disease burden when MF/SS cells show incomplete loss of CD26 and/or CD7. Recently, through the standardization effort led by the International Clinical Cytometry Society (ICCS), recommendation was made to quantify MF/SS by enumerating immunophenotypically aberrant CD4+ T‐cells, rather than CD26− or CD7− in isolation.MethodsWe compared these two quantitation methods in 309 MF/SS patients who had blood samples analyzed by flow cytometry immunophenotyping (FCI) over a 1‐year period.ResultsUsing the European Organization of Research and Treatment of Cancer (EORTC)/International Society for Cutaneous Lymphomas (ISCL) criteria, 221 (71.5%) patients had a blood stage corresponding to B0, 57 (18.4%) to B1, and 31 (10%) to B2. By FCI analysis, a total of 62 patients (20.0%) were found positive for MF/SS. Among EORTC B0 patients, 11/221 (5%) were positive by FCI (false negatives), and among EORTC Stage B1 patients, 35/57 (61%) were negative by FCI (false positives). Regarding patients positive for MF/SS cells by FCI, there was an overall excellent correlation (r = .999, p < .001) between the EORTC/ISCL method and FCI method; however, four (6.5%) patients would have an altered B stage between B0 and B1.ConclusionThe MF/SS cell quantification method using immunophenotypic aberrancies, as recommended by the ICCS, allows to distinguish MF/SS cells from background benign T‐cells and enables for more accurate staging, especially among patients currently being considered to have B0 and B1 stage diseases.
Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease
Vermunt, Lisa , Dicks, Ellen , Wang, Guoqiao , Dincer, Aylin , Flores, Shaney , Keefe, Sarah , Berman, Sarah , Cash, David M. , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fox, Nick C. , Graff‐Radford, Neill R. , Hassenstab, Jason , Laske, Christoph , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Morris, John C. , Noble, James M. , Perrin, Richard J. , Visser, Pieter Jelle , Bateman, Randall J. , Gordon, Brian A. , (DIAN), Dominantly Inherited Alzheimer Network, Amtashar, Fatima, Bodge, Courtney, Brandon, Susan E. , Buck, Jill , Buckles, Virginia, Chea, Sochenda, Chrem, Patricio, Chui, Helena C., Cinco, Jake, Jack, Clifford, D’Mello, Mirelle , Donahue, Tamara, Douglas, Jane, Edigo, Noelia, Erekin-Taner, Nilufer, Fagan, Anne M. , Farlow, Marty, Farrar, Angela, Feldman, Howard , Flynn, Gigi, Franklin, Erin , Gant, Cortaiga, Gardener, Samantha L. , Gray, Julia, Gurney, Jenny , Hassenstab, Jason, Hirohara, Mie, Hornbeck, Russ C. , DiBari, Siri Houeland, Ikonomović, Snežana, Jerome, Gina, Klunk, William E. , Kuder-Buletta, Elke, Marcus, Daniel S. , Mason, Neal Scott, Maue-Dreyfus, Denise, Montoya, Lucy, Nagamatsu, Akem, Neimeyer, Katie, Norton, Joanne, Raichle, Marc, Ringman, John M. , Roh, Jee Hoon , Shiroto, Tomoyo, Sigurdson, Wendy, Sparks, Paige, Swisher, Laura, Taddei, Kevin , Wang, Peter, Weiner, Mike, Wolfsberger, Mary, Xiong, Chengjie, Tijms, Betty M , Gordon, Brian A , Cruchaga, Carlos , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Roh, Jee Hoon , Cash, David M , Feldman, Howard H , Berman, Sarah , Ghetti, Bernardino , Karch, Celeste M. , McDade, Eric , Schofield, Peter R. , Xiong, Chengjie , Scheltens, Philip , Benzinger, Tammie L.S. , Tijms, Betty M. , (DIAN), Dominantly Inherited Alzheimer Network, Allegri, Ricardo , Brandon, Susan, Brooks, William S. , Buck, Jill, Chui, Helena C. , Fujii, Hisako , Goate, Alison , Goldman, Jill , Hassenstab, Jason, Holtzman, David M. , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Kawarabayashi, Takeshi , Koeppe, Robert A. , Martins, Ralph N. , Shimada, Hiroyuki , Shoji, Mikio , Sohrabi, Hamid R. , Suzuki, Kazushi , Wang, Jen Chin C. , Xiong, Chengjie, Xu, Xiong, Noble, James M

Mayo Clinic

Brain Communications | July 15, 2020 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaa102 | PMID 32954344 Get It

Abstract Structural grey matter covariance networks provide an individual quantification of morphological patterns in the brain. The network integrity is disrupted in sporadic Alzheimer’s disease, and network properties show associations with the level of amyloid pathology and cognitive decline. Therefore, these network properties might be disease progression markers. However, it remains unclear when and how grey matter network integrity changes with disease progression. We investigated these questions in autosomal dominant Alzheimer’s disease mutation carriers, whose conserved age at dementia onset allows individual staging based upon their estimated years to symptom onset. From the Dominantly Inherited Alzheimer Network observational cohort, we selected T1-weighted MRI scans from 269 mutation carriers and 170 non-carriers (mean age 38 ± 15 years, mean estimated years to symptom onset −9 ± 11), of whom 237 had longitudinal scans with a mean follow-up of 3.0 years. Single-subject grey matter networks were extracted, and we calculated for each individual the network properties which describe the network topology, including the size, clustering, path length and small worldness. We determined at which time point mutation carriers and non-carriers diverged for global and regional grey matter network metrics, both cross-sectionally and for rate of change over time. Based on cross-sectional data, the earliest difference was observed in normalized path length, which was decreased for mutation carriers in the precuneus area at 13 years and on a global level 12 years before estimated symptom onset. Based on longitudinal data, we found the earliest difference between groups on a global level 6 years before symptom onset, with a greater rate of decline of network size for mutation carriers. We further compared grey matter network small worldness with established biomarkers for Alzheimer disease (i.e. amyloid accumulation, cortical thickness, brain metabolism and cognitive function). We found that greater amyloid accumulation at baseline was associated with faster decline of small worldness over time, and decline in grey matter network measures over time was accompanied by decline in brain metabolism, cortical thinning and cognitive decline. In summary, network measures decline in autosomal dominant Alzheimer’s disease, which is alike sporadic Alzheimer’s disease, and the properties show decline over time prior to estimated symptom onset. These data suggest that single-subject networks properties obtained from structural MRI scans form an additional non-invasive tool for understanding the substrate of cognitive decline and measuring progression from preclinical to severe clinical stages of Alzheimer’s disease.